MetaCap

Cytek Biosciences (CTKB) vs Precipio (PRPO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cytek Biosciences (CTKB) has outperformed Precipio (PRPO) over the past year, gaining 4.1% versus a loss of 29.2%. Over five years, PRPO leads with a -54.6% price change compared with -67.8% for CTKB. Cytek Biosciences is the larger company by market cap ($800.4 million vs $31.1 million), about 25.7 times the size, while Precipio is growing revenue faster (+29.8% vs +0.5%).

On valuation, Precipio trades at a lower forward P/E (44.5x vs 87.4x for Cytek Biosciences). Precipio converts more of its revenue into profit, with a net margin of -1.5% versus -33.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTKB+4.08%PRPO-29.18%
+36%-5%-47%
Nov 21, 20251 yearNov 20, 2026
CTKB-68.58%PRPO-55.74%
+4%-44%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTKB versus PRPO key metrics
MetricCTKBPRPO
Share price$6.12$17.35
Market cap$800.40M$31.11M
1-day change-3.16%-6.17%
YTD return+21.19%-24.50%
1-year return+4.08%-29.18%
5-year return-67.82%-54.58%
Forward P/E87.4344.49
EPS (TTM)$-0.63$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$201.49M$24.05M
Revenue growth (YoY)+0.52%+29.77%
Net income (latest FY)$-66.54M$-363.00K
Gross margin51.84%44.52%
Operating margin-20.04%-5.00%
Net margin-33.02%-1.51%
52-week high$6.39$33.63
52-week low$3.31$17.30
Distance from 52-week high-4.15%-48.41%
Analyst consensusbuy—
Avg. price target upside+6.21%—
Average volume1.31M79.50K
Shares outstanding130.78M1.79M
Employees70361
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Cytek Biosciences is about 25.7 times larger than Precipio by market value ($800.40M vs $31.11M).
  • CTKB has outperformed PRPO by 33.3 percentage points over the past year.
  • Precipio is more profitable, keeping -1.5 cents of every revenue dollar as net income versus -33.0 cents for Cytek Biosciences.
  • Precipio grew revenue faster in its latest fiscal year (+29.77% vs +0.52%).

About Cytek Biosciences

CTKB stock →

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 703 employees

About Precipio

PRPO stock →

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.

Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees

CTKB vs PRPO FAQ

Which is bigger, Cytek Biosciences or Precipio?

Cytek Biosciences (CTKB) is larger, with a market capitalization of $800.40M compared with $31.11M for Precipio (PRPO).

Which stock has performed better over the past year, CTKB or PRPO?

CTKB returned +4.08% over the past 12 months, compared with -29.18% for PRPO (price return, excluding dividends). Past performance does not predict future results.

Are Cytek Biosciences and Precipio in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons